Overview
- The CNIO team reported in PNAS that a three‑drug regimen produced durable tumor regression or elimination in genetically engineered mice without notable toxicity.
- The approach targets KRAS/RAS signaling on three fronts: a KRAS inhibitor, a compound that limits cell proliferation, and a drug that degrades RAS proteins.
- Reporters summarizing the study noted no resistance during treatment and no tumor recurrence for up to 200 days after stopping therapy in mice.
- Lead investigator Mariano Barbacid said the group cannot begin human trials at this stage and must further optimize dosing and assess safety.
- Independent experts welcomed the strategy as promising for a cancer with poor survival but warned that proving benefit and tolerability in people could take years.